NMDA receptor activity in neuropsychiatric disorders

Frontiers in Psychiatry

Volumn 4, Issue JUN, 2013, Pages

  Lakhan, Shaheen E ^a,b   Caro, Mario ^b   Hadzimichalis, Norell ^a  

^a Global Neuroscience Initiative Foundation   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Huntington's disease; Mood disorders; Neuropsychiatric systemic lupus erythematosus; NMDA; Psychiatry; Schizophrenia; Substance induced psychosis

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMANTADINE; AMPA RECEPTOR; AMYLOID BETA PROTEIN; ARACHIDONIC ACID; AUTOANTIBODY; BITOPERTIN; CLOZAPINE; CYCLOSERINE; DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE INHIBITOR; DEXTRO SERINE; DOPAMINE; EPHRIN RECEPTOR B2; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NERAMEXANE; NUCLEAR PROTEIN; OXIDOREDUCTASE INHIBITOR; POSTSYNAPTIC DENSITY PROTEIN 95; SARCOSINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CALCIUM TRANSPORT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; MOOD DISORDER; NERVE CELL MEMBRANE POTENTIAL; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; NEUROTRANSMISSION; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANCE INDUCED PSYCHOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; WITHDRAWAL SYNDROME;

EID: 84884564271     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00052     Document Type: Review

References (67)

1. Andreasen, J. T., Gynther, M., Rygaard, A., Bøgelund, T., Nielsen, S. D., Clausen, R. P., et al. (2013). Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neurosci. Lett. doi:10.1016/j.neulet.2013.04.045
2. Basselin, M., Chang, L., Bell, J. M., and Rapoport, S. I. (2006). Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31, 1659-1674. doi:10.1038/sj.npp.1300920
3. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., and Martin, J. B. (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171. doi:10.1038/321168a0
4. Boulay, D., Bergis, O., Avenet, P., and Griebel, G. (2010). The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35, 416-427. doi:10.1038/npp.2009.144
5. Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., Mcmahon, R. P., et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593-1602. doi:10.1176/appi.ajp.2007.06081358
6. Butterfield, D. A., and Pocernich, C. B. (2003). The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 17, 641-652. doi:10.2165/00023210-200317090-00004
7. Carmichael, J., Chatellier, J., Woolfson, A., Milstein, C., Fersht, A. R., and Rubinsztein, D. C. (2000). Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 97, 9701-9705. doi:10.1073/pnas.170280697
8. Cisse, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., et al. (2011). Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52. doi:10.1038/nature09635
9. Coyle, J. T., and Schwarcz, R. (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244-246. doi:10.1038/263244a0
10. Coyle, J. T., Tsai, G., and Goff, D. (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 1003, 318-327. doi:10.1196/annals.1300.020
11. Davies, S., and Ramsden, D. B. (2001). Huntington's disease. Mol. Pathol. 54, 409-413.
12. Dongen, A. M. V. (2009). Biology of the NMDA Receptor. Boca Raton, FL: CRC Press.
13. D'Souza, D. C., Singh, N., Elander, J., Carbuto, M., Pittman, B., de Haes, J., et al. (2012). Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 37, 1036-1046. doi:10.1038/npp.2011.295
14. Fitzgerald, L. W., Deutch, A. Y., Gasic, G., Heinemann, S. F., and Nestler, E. J. (1995). Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15, 2453-2461.
15. Fleischhacker, W. W. (1995). New drugs for the treatment of schizophrenic patients. Acta Psychiatr. Scand. Suppl. 388, 24-30. doi:10.1111/j.1600-0447.1995.tb05941.x
16. Gaynes, B. N., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Balasubramani, G. K., Mcgrath, P. J., et al. (2008). Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J. Gen. Intern. Med. 23, 551-560. doi:10.1007/s11606-008-0522-3
17. Gaynor, B., Putterman, C., Valadon, P., Spatz, L., Scharff, M. D., and Diamond, B. (1997). Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc. Natl. Acad. Sci. U.S.A. 94, 1955-1960. doi:10.1073/pnas.94.5.1955
18. Gilmour, G., Dix, S., Fellini, L., Gastambide, F., Plath, N., Steckler, T., et al. (2012). NMDA receptors, cognition and schizophrenia - testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62, 1401-1412. doi:10.1016/j.neuropharm.2011.03.015
19. Gogas, K. R. (2006). Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 6, 68-74. doi:10.1016/j.coph.2005.11.001
20. Gordon-Krajcer, W., Salinska, E., and Lazarewicz, J. W. (2002). N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro - superfusion study. Folia Neuropathol. 40, 13-17.
21. Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., et al. (1983). A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306, 234-238. doi:10.1038/306234a0
22. Hardy, J., Duff, K., Hardy, K. G., Perez-Tur, J., and Hutton, M. (1998). Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1, 355-358. doi:10.1038/3743
23. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi:10.1126/science.1072994
24. Iqbal, N., and van Praag, H. M. (1995). The role of serotonin in schizophrenia. Eur. Neuropsychopharmacol. 5(Suppl.), 11-23. doi:10.1016/0924-977X(95)00027-M
25. Katz, J. B., Limpanasithikul, W., and Diamond, B. (1994). Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med. 180, 925-932. doi:10.1084/jem.180.3.925
26. Kemp, J. A., and McKernan, R. M. (2002). NMDA receptor pathways as drug targets. Nat. Neurosci. 5(Suppl.), 1039-1042. doi:10.1038/nn936
27. Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., and Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382. doi:10.1016/0304-3940(80)90178-0
28. Kowal, C., Degiorgio, L. A., Lee, J. Y., Edgar, M. A., Huerta, P. T., Volpe, B. T., et al. (2006). Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U.S.A. 103, 19854-19859. doi:10.1073/pnas.0608397104
29. Kowal, C., Degiorgio, L. A., Nakaoka, T., Hetherington, H., Huerta, P. T., Diamond, B., et al. (2004). Cognition and immunity; antibody impairs memory. Immunity 21, 179-188. doi:10.1016/j.immuni.2004.07.011
30. Kretschmer, B. D. (1999). Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors. J. Neurochem. 73, 839-848. doi:10.1046/j.1471-4159.1999.0730839.x
31. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214. doi:10.1001/archpsyc.1994.03950030035004
32. Lahti, A. C., Holcomb, H. H., Medoff, D. R., and Tamminga, C. A. (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6, 869-872. doi:10.1097/00001756-199504190-00011
33. Lechner, S. M. (2006). Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr. Opin. Pharmacol. 6, 75-81. doi:10.1016/j.coph.2005.11.002
34. Levine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., et al. (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515-532. doi:10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F
35. Levinson, D. F. (1991). Pharmacologic treatment of schizophrenia. Clin. Ther. 13, 326-352.
36. Li, F., and Tsien, J. Z. (2009). Memory and the NMDA receptors. N. Engl. J. Med. 361, 302-303. doi:10.1056/NEJMcibr0902052
37. Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964. doi:10.1126/science.1190287
38. Lieberman, J. A., Stroup, T. S., Mcevoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223. doi:10.1056/NEJMoa051688
39. Lindenmayer, J. P. (1995). New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. Suppl. 388, 15-19. doi:10.1111/j.1600-0447.1995.tb05939.x
40. Lipton, S. A., and Rosenberg, P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613-622. doi:10.1056/NEJM199403033300907
41. Long, K. D., Mastropaolo, J., Rosse, R. B., Manaye, K. F., and Deutsch, S. I. (2006). Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain. Brain Res. Bull. 69, 626-630. doi:10.1016/j.brainresbull.2006.03.007
42. Luby, E. D., Cohen, B. D., Rosenbaum, G., Gottlieb, J. S., and Kelley, R. (1959). Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 81, 363-369. doi:10.1001/archneurpsyc.1959.02340150095011
43. Mak, A., Ho, R. C. M., and Lau, C. S. (2009). Clinical implications of neuropsychiatric systemic lupus erythematosus. Adv. Psychiatr. Treat. 15, 451-458. doi:10.1192/apt.bp.108.005785
44. Malinow, R. (2012). New developments on the role of NMDA receptors in Alzheimer's disease. Curr. Opin. Neurobiol. 22, 559-563. doi:10.1016/j.conb.2011.09.001
45. Martucci, L., Wong, A. H., De Luca, V., Likhodi, O., Wong, G. W., King, N., et al. (2006). N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr. Res. 84, 214-221. doi:10.1016/j.schres.2006.02.001
46. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., Mcdonald, B. L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249. doi:10.1073/pnas.82.12.4245
47. Meltzer, H. Y., and Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2, 19-76. doi:10.1093/schbul/2.1.19
48. Michael, N., Erfurth, A., Ohrmann, P., Gossling, M., Arolt, V., Heindel, W., et al. (2003). Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl.) 168, 344-346. doi:10.1007/s00213-003-1440-z
49. Millan, M. J. (2005). N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl.) 179, 30-53. doi:10.1007/s00213-005-2199-1
50. Niemi-Pynttari, J. A., Sund, R., Putkonen, H., Vorma, H., Wahlbeck, K., and Pirkola, S. P. (2013). Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J. Clin. Psychiatry 74, e94-e99. doi:10.4088/JCP.12m07822
51. NLM. (2013). ClinicalTrials.gov. Available at: http://ClinicalTrials.gov [accessed]
52. Nolt, M. J., Lin, Y., Hruska, M., Murphy, J., Sheffler-Colins, S. I., Kayser, M. S., et al. (2011). EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J. Neurosci. 31, 5353-5364. doi:10.1523/JNEUROSCI.0282-11.2011
53. Paoletti, P., and Neyton, J. (2007). NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7, 39-47. doi:10.1016/j.coph.2006.08.011
54. Petri, M., Naqibuddin, M., Sampedro, M., Omdal, R., and Carson, K. A. (2011). Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin. Arthritis Rheum. 41, 194-202. doi:10.1016/j.semarthrit.2011.02.005
55. Pinard, E., Alanine, A., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., et al. (2010). Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J. Med. Chem. 53, 4603-4614. doi:10.1021/jm100210p
56. Popescu, A., and Kao, A. H. (2011). Neuropsychiatric systemic lupus erythematosus. Curr. Neuropharmacol. 9, 449-457. doi:10.2174/157015911796557984
57. Rabe-Jablonska, J., Mirek, M., and Pawelczyk, T. (2012). Risk factors of schizophrenia development in patients with amphetamines dependence and psychosis (amphetamine-induced psychosis and schizophrenia), and without psychosis. Psychiatr. Pol. 46, 571-584.
58. Rapoport, S. I., and Bosetti, F. (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592-596. doi:10.1001/archpsyc.59.7.592
59. Sanacora, G., Zarate, C. A., Krystal, J. H., and Manji, H. K. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7, 426-437. doi:10.1038/nrd2462
60. Schuler, T., Mesic, I., Madry, C., Bartholomaus, I., and Laube, B. (2008). Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly. J. Biol. Chem. 283, 37-46. doi:10.1074/jbc.M703539200
61. Schwartz, T. L., Sachdeva, S., and Stahl, S. M. (2012). Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 3:195. doi:10.3389/fphar.2012.00195
62. Shefner, R., Kleiner, G., Turken, A., Papazian, L., and Diamond, B. (1991). A novel class of anti-DNA antibodies identified in BALB/c mice. J. Exp. Med. 173, 287-296. doi:10.1084/jem.173.2.287
63. Stahl, S. M. (2008). Depression and Bipolar Disorder: Stahl's Essential Psychopharmacology. Cambridge: Cambridge University Press.
64. Stephenson, F. A., Cousins, S. L., and Kenny, A. V. (2008). Assembly and forward trafficking of NMDA receptors (review). Mol. Membr. Biol. 25, 311-320. doi:10.1080/09687680801971367
65. Sun, Y., Savanenin, A., Reddy, P. H., and Liu, Y. F. (2001). Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718. doi:10.1074/jbc.M103501200
66. Tsapakis, E. M., and Travis, M. J. (2002). Glutamate and psychiatric disorders. Adv. Psychiatr. Treat. 8, 189-197. doi:10.1192/apt.8.3.189
67. Zarate, C. A. Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864. doi:10.1001/archpsyc.63.8.856